SCHEMBL6057147

SCHEMBL6057147

CCCCOC(=O)c1ccc(Cl)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 5/20 0.72
TSHR P16473 4/20 0.72
LMNA P02545 2/20 0.72
CYP1A2 P05177 2/20 0.72
CYP2C19 P33261 2/20 0.72
CYP2D6 P10635 1/20 0.72
MAPK1 P28482 1/20 0.72
NR1H2 P55055 1/20 0.72
RNASEL Q05823 1/20 0.72
SMN1; SMN2 Q16637 1/20 0.72
CYP3A4 P08684 1/20 0.70
CYP2C9 P11712 1/20 0.70
PDE4D Q08499 1/20 0.70
GAA P10253 1/20 0.69
HPGD P15428 1/20 0.62
RECQL P46063 1/20 0.62
ALDH1A1 P00352 2/20 0.61
NPC1 O15118 1/20 0.61
MAPT P10636 1/20 0.61
RAB9A P51151 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6057260 0.95 ALDH1A1 (0.69) ESR1TSHRLMNACYP1A2CYP2C19
SCHEMBL6244199 0.93 ALDH1A1 (0.71) ESR1TSHRLMNACYP1A2CYP2C19
SCHEMBL27695864 0.93 ALDH1A1 (0.71) ESR1TSHRLMNACYP1A2CYP2C19
SCHEMBL27677218 0.93 ALDH1A1 (0.71) ESR1TSHRLMNACYP1A2CYP2C19
SCHEMBL5710046 0.93 ALDH1A1 (0.71) ESR1TSHRLMNACYP1A2CYP2C19
SCHEMBL7517603 0.93 ALDH1A1 (0.71) ESR1TSHRLMNACYP1A2CYP2C19
SCHEMBL28506813 0.93 ALDH1A1 (0.71) ESR1TSHRLMNACYP1A2CYP2C19
SCHEMBL14029067 0.92 LMNA (0.62) ESR1TSHRLMNACYP1A2CYP2C19
SCHEMBL15672808 0.91 ESR1 (0.60) ESR1TSHRLMNACYP1A2CYP2C19
SCHEMBL37476 0.91 ESR1 (0.85) ESR1TSHRLMNACYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102834420-B Internal and external donor compounds for olefin polymerization catalysts ii BASF CORP. (US) 2014-10-22 CN claimed
US-8569195-B2 Internal and external donor compounds for olefin polymerization catalysts II BASF CORPORATION (US) 2013-10-29 US claimed
CN-102834420-A Internal and external donor compounds for olefin polymerization catalysts ii BASF CORP 2012-12-19 CN claimed
CN-1301991-C Piperidine derivatives, process for preparation thereof, and pharmaceutical composition for alzheimer's disease containing the same STC NARA CO LTD (KR) 2007-02-28 CN claimed
CN-1571784-A Piperidine derivatives, process for preparing the same, and pharmaceutical composition for treating alzheimer's disease containing the same STC NARA CO LTD (KR) 2005-01-26 CN claimed
US-12485157-B2 Method of treating COVID-19 PFIZER INC. (US) 2025-12-02 US disclosed
CN-117860750-A Application of hydrogenated quinibutyl p-chlorobenzoate in preparation of antitumor drugs 兰州大学 2024-04-12 CN disclosed
CN-117860750-A Application of hydrogenated quinibutyl p-chlorobenzoate in preparation of antitumor drugs 兰州大学 2024-04-12 CN disclosed
US-20230105838-A1 Method of Treating COVID-19 PFIZER INC. (US) 2023-04-06 US disclosed
EP-2782938-B1 HIGH ACTIVITY CATALYST FOR OLEFIN POLYMERIZATION BASF CORP (US) 2016-08-31 EP disclosed
WO-2015129813-A1 DEUTERATION METHOD AND DEUTERATION CATALYST 国立大学法人 長崎大学 2015-09-03 WO disclosed
CN-104540855-A Catalyst components for the polymerization of olefins BASELL POLIOLEFINE SPA 2015-04-22 CN disclosed
EP-1192196-A1 PROCESS FOR PRODUCING ETHYLENE/OLEFIN INTERPOLYMERS EASTMAN CHEMICAL COMPANY (US) 2002-04-03 EP disclosed
US-20010051587-A1 Procatalysts, catalyst systems, and use in olefin polymerization WESTLAKE LONGVIEW CORPORATION 2001-12-13 US disclosed
US-20010031841-A1 Procatalysts, catalyst systems, and use in olefin polymerization WESTLAKE LONGVIEW CORPORATION 2001-10-18 US disclosed
US-20010029286-A1 Procatalysts, catalyst systems, and use in OLEFIN polymerization EASTMAN CHEMICAL COMPANY, A CORP. OF DELAWARE 2001-10-11 US disclosed
US-20010025005-A1 Procatalysts, catalyst systems, and use in olefin polymerization EASTMAN CHEMICAL COMPANY, A CORPORATION OF DELAWARE 2001-09-27 US disclosed
US-6271321-B1 CATALYTIC POLYMERIZATION OR COPOLYMERIZATION OF ETHYLENE AND OLEFIN MONOMERS EASTMAN CHEMICAL COMPANY 2001-08-07 US disclosed
WO-2000075204-A1 PROCESS FOR PRODUCING ETHYLENE/OLEFIN INTERPOLYMERS EASTMAN CHEMICAL COMPANY (US) 2000-12-14 WO disclosed
US-3993437-A Process for the dyeing of polyamide fibers with sulphur dyestuffs CASSELLA FARBWERKE MAINKUR AKTIENGESELLSCHAFT (DT) 1976-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12485157-B2 Method of treating COVID-19 ACE2, ACE, TMPRSS2 ESR1 3827/4885TSHR 4625/4885LMNA 2019/4885
US-20230105838-A1 Method of Treating COVID-19 ACE2, ACE, TMPRSS2 ESR1 3827/4885TSHR 4625/4885LMNA 2019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.